List view / Grid view
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
New research reveals how B cells balance mutation and clonal expansion to refine their antibodies. This discovery could lead to more targeted and effective vaccine designs for various diseases.
The new technique could be adapted to produce a wide range of antibodies to combat chronic conditions like HIV.
The new study demonstrated that a small molecule inhibitor, BLZ945, could be used as a potential therapeutic to achieve viral clearance.
A new assay has been developed which enables the detailing of intact proviral genomes of under-studied HIV strains.
This report provides insights into current research and future prospects from potential breakthroughs to global collaboration in pandemic preparedness.
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
Researchers have created a nanomedicine loaded with siRNAs, which demonstrated a 73 percent reduction in HIV replication.
Researchers discover a mechanism that could be exploited for targeting other viruses that build capsids to hide from host defences.
The discovery that HIV capsids are importin-like transporters could be exploited for improved AIDS therapies.
The new findings could help preventive and therapeutic HIV vaccine design and development, and HIV immunotherapy approaches.
New Salk Institute, US, research could lead to the development of new HIV therapeutics that overcome resistance to existing drugs.
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
An experimental HIV vaccine, delivered as increasing doses over several days, led to long-lasting and diverse antibody production in monkeys.
Researchers in the US have developed a potential HIV vaccine approach that aims to prompt the creation of broadly neutralising antibodies via mRNA.
